Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales

Kiran Samra,Amy Macdougall,Georgia Peakman,Arabella Bouzigues,Martina Bocchetta,David M Cash,Caroline V Greaves,Rhian S Convery,John C van Swieten,Lize C Jiskoot,Harro Seelaar,Fermin Moreno,Raquel Sánchez-Valle,Robert Laforce,Caroline Graff,Mario Masellis,Maria Carmela Tartaglia,James B Rowe,Barbara Borroni,Elizabeth Finger,Matthis Synofzik,Daniela Galimberti,Rik Vandenberghe,Alexandre de Mendonca,Christopher R Butler,Alexander Gerhard,Simon Ducharme,Isabelle Le Ber,Pietro Tiraboschi,Isabel Santana,Florence Pasquier,Johannes Levin,Markus Otto,Sandro Sorbi,Jonathan D Rohrer,Lucy L Russell,Genetic FTD Initiative (GENFI),Genetic FTDInitiative (GENFI),Annabel Nelson,David L Thomas,Emily Todd,Hanya Benotmane,Jennifer Nicholas,Rachelle Shafei,Carolyn Timberlake,Thomas Cope,Timothy Rittman,Alberto Benussi,Enrico Premi,Roberto Gasparotti,Silvana Archetti,Stefano Gazzina,Valentina Cantoni,Andrea Arighi,Chiara Fenoglio,Elio Scarpini,Giorgio Fumagalli,Vittoria Borracci,Giacomina Rossi,Giorgio Giaccone,Giuseppe Di Fede,Paola Caroppo,Sara Prioni,Veronica Redaelli,David Tang-Wai,Ekaterina Rogaeva,Miguel Castelo-Branco,Morris Freedman,Ron Keren,Sandra Black,Sara Mitchell,Christen Shoesmith,Robart Bartha,Rosa Rademakers,Jackie Poos,Janne M Papma,Lucia Giannini,Rick van Minkelen,Yolande Pijnenburg,Benedetta Nacmias,Camilla Ferrari,Cristina Polito,Gemma Lombardi,Valentina Bessi,Michele Veldsman,Christin Andersson,Hakan Thonberg,Linn Öijerstedt,Vesna Jelic,Paul Thompson,Tobias Langheinrich,Albert Lladó,Anna Antonell,Jaume Olives,Mircea Balasa,Nuria Bargalló,Sergi Borrego-Ecija,Ana Verdelho,Carolina Maruta,Catarina B Ferreira,Gabriel Miltenberger,Frederico Simões do Couto,Alazne Gabilondo,Ana Gorostidi,Jorge Villanua,Marta Cañada,Mikel Tainta,Miren Zulaica,Myriam Barandiaran,Patricia Alves,Benjamin Bender,Carlo Wilke,Lisa Graf,Annick Vogels,Mathieu Vandenbulcke,Philip Van Damme,Rose Bruffaerts,Koen Poesen,Pedro Rosa-Neto,Serge Gauthier,Agnès Camuzat,Alexis Brice,Anne Bertrand,Aurélie Funkiewiez,Daisy Rinaldi,Dario Saracino,Olivier Colliot,Sabrina Sayah,Catharina Prix,Elisabeth Wlasich,Olivia Wagemann,Sandra Loosli,Sonja Schönecker,Tobias Hoegen,Jolina Lombardi,Sarah Anderl-Straub,Adeline Rollin,Gregory Kuchcinski,Maxime Bertoux,Thibaud Lebouvier,Vincent Deramecourt,Beatriz Santiago,Diana Duro,Maria João Leitão,Maria Rosario Almeida,Miguel Tábuas-Pereira,Sónia Afonso

DOI: https://doi.org/10.1136/jnnp-2022-330152

Abstract:Background: Current clinical rating scales in frontotemporal dementia (FTD) often do not incorporate neuropsychiatric features and may therefore inadequately measure disease stage. Methods: 832 participants from the Genetic FTD Initiative (GENFI) were recruited: 522 mutation carriers and 310 mutation-negative controls. The standardised GENFI clinical questionnaire assessed the frequency and severity of 14 neuropsychiatric symptoms: visual, auditory, and tactile hallucinations, delusions, depression, anxiety, irritability/lability, agitation/aggression, euphoria/elation, aberrant motor behaviour, hypersexuality, hyperreligiosity, impaired sleep, and altered sense of humour. A principal component analysis (PCA) was performed to identify key groupings of neuropsychiatric and behavioural items in order to create a new neuropsychiatric module that could be used as an addition to the Clinical Dementia Rating (CDR) plus National Alzheimer's Coordinating Center Behaviour and Language Domains (NACC FTLD) rating scale. Results: Overall, 46.4% of mutation carriers had neuropsychiatric symptoms (51.6% C9orf72, 40.8% GRN, 46.6% MAPT) compared with 24.5% of controls. Anxiety and depression were the most common in all genetic groups but fluctuated longitudinally and loaded separately in the PCA. Hallucinations and delusions loaded together, with the remaining neuropsychiatric symptoms loading with the core behavioural features of FTD. These results suggest using a single 'psychosis' neuropsychiatric module consisting of hallucinations and delusions. Adding this to the CDR plus NACC FTLD, called the CDR plus NACC FTLD-N, leads to a number of participants being scored more severely, including those who were previously considered asymptomatic now being scored as prodromal. Conclusions: Neuropsychiatric symptoms occur in mutation carriers at all disease stages across all three genetic groups. However, only psychosis features provided additional staging benefit to the CDR plus NACC FTLD. Inclusion of these features brings us closer to optimising the rating scale for use in trials.